Similarly, evidence from multiple myeloma studies indicates that treatment with belantamab mafodotin can induce B-cell maturation antigen (BCMA) loss or escape, which is strongly associated with subsequent treatment failure[12]. The gene discussed is TNFRSF17; the disease is plasma cell myeloma.